John Duke Purchases 5,000 Shares of Harvard Bioscience (NASDAQ:HBIO) Stock

Harvard Bioscience, Inc. (NASDAQ:HBIO) CEO John Duke acquired 5,000 shares of Harvard Bioscience stock in a transaction that occurred on Monday, March 16th. The shares were purchased at an average cost of $5.01 per share, for a total transaction of $25,050.00. Following the purchase, the chief executive officer directly owned 105,000 shares of the company’s stock, valued at approximately $526,050. This trade represents a 5.00% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Harvard Bioscience Stock Performance

NASDAQ HBIO traded down $0.14 during mid-day trading on Tuesday, reaching $4.87. 81,266 shares of the stock were exchanged, compared to its average volume of 46,616. The stock has a market capitalization of $21.78 million, a PE ratio of -3.80 and a beta of 1.51. Harvard Bioscience, Inc. has a 1-year low of $2.81 and a 1-year high of $9.50. The business’s fifty day simple moving average is $5.67 and its 200 day simple moving average is $5.66.

Wall Street Analyst Weigh In

Several equities analysts recently commented on HBIO shares. Wall Street Zen upgraded Harvard Bioscience from a “hold” rating to a “buy” rating in a research note on Monday, November 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Harvard Bioscience in a research note on Monday, December 29th. Zacks Research upgraded Harvard Bioscience to a “hold” rating in a report on Thursday, December 11th. New Street Research set a $6.00 price objective on shares of Harvard Bioscience in a research note on Friday. Finally, Benchmark cut their price objective on shares of Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating on the stock in a report on Friday. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Harvard Bioscience has an average rating of “Hold” and an average price target of $6.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE grew its position in Harvard Bioscience by 44.4% during the fourth quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock valued at $82,000 after acquiring an additional 11,948 shares during the period. Acadian Asset Management LLC raised its holdings in shares of Harvard Bioscience by 7.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,077,069 shares of the medical instruments supplier’s stock worth $606,000 after purchasing an additional 78,276 shares during the period. Strs Ohio purchased a new position in shares of Harvard Bioscience in the 1st quarter worth about $117,000. Marshall Wace LLP acquired a new position in shares of Harvard Bioscience in the 2nd quarter valued at about $61,000. Finally, Jane Street Group LLC lifted its stake in shares of Harvard Bioscience by 491.9% in the 2nd quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 58,785 shares in the last quarter. Institutional investors and hedge funds own 80.87% of the company’s stock.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.